Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Ibrahim Diakite"'
Autor:
Ibrahim Diakite, Bruno Martins, Kwame Owusu-Edusei, Cody Palmer, Oscar Patterson-Lomba, Andres Gomez-Lievano, Abigail Zion, Ryan Simpson, Vincent Daniels, Elamin Elbasha
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 5, Pp 965-990 (2024)
Abstract Human papillomavirus (HPV) is a common sexually transmitted virus that can cause cervical cancer and other diseases. Dynamic transmission models (DTMs) have been developed to evaluate the health and economic impacts of HPV vaccination. These
Externí odkaz:
https://doaj.org/article/a404444231294581802c4e494ba58bfa
Autor:
Ibrahim Diakite, Jeffrey Kyle, Sujian Situ, Peng Bai, Xingxing Zhang, Wei Wang, Vincent Daniels
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
The high prevalence of human papillomavirus (HPV) infection in China suggests there would be a substantial positive health impact of widespread vaccination against HPV. We adapted a previously described dynamic transmission model of the natural histo
Externí odkaz:
https://doaj.org/article/fa608f8558bb4772adfdc3d979b2a8c5
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 10, Iss 8, p e0004866 (2016)
BACKGROUND:During the 2014 Ebola virus disease (EVD) outbreak, policy-makers were confronted with difficult decisions on how best to test the efficacy of EVD vaccines. On one hand, many were reluctant to withhold a vaccine that might prevent a fatal
Externí odkaz:
https://doaj.org/article/378e883b312e428aab0d773205c9080f
Publikováno v:
PLoS Computational Biology, Vol 12, Iss 1, p e1004710 (2016)
The adaptive landscape analogy has found practical use in recent years, as many have explored how their understanding can inform therapeutic strategies that subvert the evolution of drug resistance. A major barrier to applications of these concepts i
Externí odkaz:
https://doaj.org/article/4cc2e798174b4caaac5c1c34919752e6
Autor:
Olalekan O. Oluwole, Rongzhe Liu, Ibrahim Diakite, Chaoling Feng, Anik Patel, Iman Nourhussein, Julia Thornton Snider, Frederick L. Locke
Publikováno v:
Journal of Medical Economics. 25:541-551
This study evaluated from a US payer perspective the cost-effectiveness of two chimeric antigen receptor T (CAR T) cell therapies, axicabtagene ciloleucel (axi-cel) versus lisocabtagene maraleucel (liso-cel), for the treatment of adult patients with
Autor:
Madiassa Konate, Amadou Traore, Moussa Samake, Abdoulaye Diarra, Boubacar Karembé, Amadou Bah, Boubacar Yoro Sidibé, Kadiatou Doumbia, Tany Koné, Amadou Maiga, Zakari Saye, Arouna Doumbia, Ibrahim Diakite, Bakary T. Dembelé, Alhassane Traore, Lassana Kante, Adegné Togo
Publikováno v:
Surgical Science. 13:15-22
Autor:
Madiassa Konate, Amadou Traore, Moussa Samake, Abdoulaye Diarra, Idrissa Tounkara Boubacar Karembé, Amadou Bah, Boubacar Yoro Sidibé, Tany Koné, Amadou Maiga, Zakari Saye, Sana Kouriba, Arouna Doumbia, Ibrahim Diakite, Bakary T. Dembelé, Alhassane Traore, Lassana Kante, Adegné Togo
Publikováno v:
Surgical Science. 13:188-197
Autor:
Dominik Lautsch, Yufei Wang, Adnan Alsumali, Andrew Briggs, Ibrahim Diakite, Rongzhe Liu, Dipen Patel, Laurence M Djatche
Publikováno v:
Pharmacoeconomics
Objective Given the high economic burden of disease among adult patients with chronic heart failure with reduced ejection fraction (HFrEF) following a worsening heart failure event in the US, this study aimed to estimate the cost effectiveness of ver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::defed197698243ebb7376e0c201c823c
Publikováno v:
Journal of managed carespecialty pharmacy. 27(11)
BACKGROUND: The efficacy of intravenous (IV) vedolizumab vs subcutaneous (SC) adalimumab for the treatment of moderately to severely active ulcerative colitis (UC) was assessed in the VARSITY clini...
Autor:
Marc F. Botteman, Frederick L. Locke, Rongzhe Liu, Olalekan O. Oluwole, Julia Thornton Snider, Ibrahim Diakite
To assess from a US payer perspective the cost-effectiveness of the chimeric antigen receptor T (CAR T)-cell therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) to treat relapsed or refractory (r/r) large B-cell lymphoma (LBCL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff0144c2d1ece9596a055230e387fbf2